AARDAardvark Therapeutics Inc
AARD
Aardvark Therapeutics Inc122
Mkt Cap
$114.1MVolume
213,934.0052W High
$17.9452W Low
$3.35PE Ratio
-1.97AARD Fundamentals
Price
$5.23Prev Close
$4.99Open
$5.1050D MA
$7.14Beta
1.50Avg. Volume
528,806.67EPS (Annual)
-$2.64P/B
1.07Rev/Employee
$0.00$176.74
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Sees Large Decline in Short Interest
Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) was the target of a large decrease in short interest in the month of March. As of March 31st, there was short interest totaling 1,132,986...
MarketBeat·3d ago
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman PR Newswire SAN FRANCISCO, April 10, 2026 SAN...
PR Newswire·8d ago
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Rating of "Moderate Buy" by Analysts
Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen research firms that are currently covering the stock...
MarketBeat·18d ago
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Sees Significant Drop in Short Interest
Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling...
MarketBeat·21d ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·24d ago
BTIG Research Reaffirms Buy Rating for Aardvark Therapeutics (NASDAQ:AARD)
BTIG Research reaffirmed a "buy" rating and set a $9.00 target price on shares of Aardvark Therapeutics in a research note on Tuesday...
MarketBeat·26d ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·1mo ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·1mo ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·1mo ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·1mo ago
<
1
2
...
>